Sorrento Therapeutics is a biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases. The Company's lead programs consist of four Phase III BioSimilar/BioBetter antibodies. It is also advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).